Lymphocyte Recovery Kinetics in Patients Undergoing Myeloablative Conditioning and Allogeneic Stem Cell Transplantation

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 5467-5467
Author(s):  
David Jared Kobulnicky ◽  
Roy T Sabo ◽  
Ali S Shubar Ali ◽  
Catherine H. Roberts ◽  
Allison F Scalora ◽  
...  

Abstract Immune reconstitution following stem cell transplantation (SCT) may be considered as a dynamical system in which future events are predicated on all the preceding past events. In turn, lymphoid reconstitution over time will determine the clinical trajectory an individual patient might take. Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic (sigmoidal) pattern of exponential growth followed by a plateau. This study aims to understand whether logistic modeling of lymphocyte recovery following SCT can be used to predict outcomes and thus guide therapies to minimize the competing pathologies of graft vs. host disease (GVHD) and relapse. A retrospective analysis of allogeneic SCT performed from 2008 to 2011 was undertaken to compare lymphoid recovery and clinical outcomes in 82 patients with acute myelogenous leukemia, acute lymphocytic leukemia and myelodysplastic syndromes. Using Prism software, a logistic curve was successfully fitted to the absolute lymphocyte count recovery in all patients. Patients were classified according to the magnitude and rate of lymphoid recovery; Type A achieved an absolute lymphocyte count (ALC) of > 1000/mcrL by day 45; Type B an ALC 500 < x < 1000 /mcrL and Type C, an ALC <500/mcrL. There was a significant difference in overall survival (Kaplan-Meier p=0.002) and one-year survival whereby 32/45 (71%) of Type A, 15/26 (58%) of Type B and 2/11 (18%) of Type C remained alive (p=.006). There was no difference in cGVHD (p=0.22) or relapse (p=0.52) incidence between patients with patterns A and B; all patients with pattern C experienced death, relapse or cGVHD within one year. Acute Lymphoblastic Leukemia as initial diagnosis (p=0.04), unrelated donor (p=0.007), mycophenolate mofetil GVHD prophylaxis (p=0.04) predicted type C pattern. Within this logistic framework, cellular recovery is characterized by the parameters R (slope of ascent), a (time of maximal ascent) and K ( plateau), the 'steady state' lymphocyte count. Mean K was significantly different between pattern type whereby pattern A had mean ALC of 1760 /mcrL, pattern B an ALC of 868 and pattern C, an ALC of 262 (p=0.0029) respectively. Neither parameters, a nor R were significantly different between pattern types. CMV, acute GVHD and relapse all were associated with deviation from logistic behavior. Weaning of tacrolimus post-transplant was associated with a second, separate phase of logistic expansion of ALC in some patients. Low K or steady state lymphocyte count is a risk factor for relapse and early death. Pattern B have no increased risk of GVHD compared to Pattern A. Assesing lymphoid reconstitution as a logistic function of time allows dynamic association of donor immune recovery with clinical outcomes and may allow for preemptive adjustments in immune suppresssion or use donor lymphocyte infusions to optimize clinical outcomes. Figure 1. Kaplan-Meier survival plot of patients grouped according to ALC recovery pattern. Figure 1. Kaplan-Meier survival plot of patients grouped according to ALC recovery pattern. Figure 2. Figure 2. Disclosures Neale: CHRB: Research Funding.

2016 ◽  
Author(s):  
David J Kobulnicky ◽  
Roy T Sabo ◽  
Shashank Sharma ◽  
Ali S Shubar Ali ◽  
Kristen Kobulnicky ◽  
...  

AbstractLymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the steady state lymphocyte count. A retrospective analysis of allogeneic SCT performed from 2008 to 2013 was undertaken to compare lymphoid recovery and clinical outcomes in 131 patients with acute myelogenous leukemia, acute lymphocytic leukemia and myelodysplastic syndromes. Using Prism software, a logistic curve was successfully fit to the absolute lymphocyte count recovery in all patients. Patients were classified according to the magnitude and rate of lymphoid recovery; pattern A achieved an ALC of > 1000/uL by day 45; pattern B an ALC 500 < x < 1000 /uL and pattern C, an ALC <500/uL. Pattern A was characterized by a higher mean K (p < 0.0001) compared with patterns B & C. Patients with patterns B and C were more likely to have mixed T cell chimerism at ninety days following SCT (p=0.01). There was a trend towards improved survival, (and relapse-free survival) in those with pattern A and B at one year compared to pattern C (p = 0.073). There was no difference in cGVHD (p=0.42) or relapse (p=0.45) between pattern types. CMV, aGVHD and relapse all were heralded by deviation from logistic behavior. Pattern C patients were more likely to require donor lymphocyte infusion (p=0.017). Weaning of Tacrolimus post-transplant was associated with a second, separate logistic expansion in some patients. This study demonstrated that lymphoid reconstitution follows a prototypical logistic recovery and that pattern observed correlates with T cell chimerism and need for DLI, and may influence survival.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4973-4973
Author(s):  
Elias H. Atta ◽  
Cláudia J.P.B. Coelho ◽  
Silvia M.P. Sarcinelli ◽  
Cláudia A. Máximo ◽  
Alexandre M. Azevedo ◽  
...  

Abstract Background: Early absolute lymphocyte count (ALC) recovery after autologous peripheral hematopoietic stem cell transplantation (ASCT) has been reported as an independent prognostic factor for overall survival and progression-free survival for patients with hematological and non-hematological cancers. Early immune reconstitution appears to have a protective effect against residual disease after ASCT. End points: Assessment of factors impacting on early ALC recovery after ASCT. Methods: Retrospective analysis of the ASCT procedures done between 2000 and 2007 in Hemorio. Early lymphocyte recovery (ELR) was defined as an ALC ≥500/μL at day 12 after ASCT. Results: A total of 53 of 66 consecutive ASCT (80,3%) were eligible for this study. Of the 53 ASCT, 9 were for lymphoma, 22 for multiple myeloma and 22 for acute myelogenous leukemia. Median age of the group was 34 years (range: 13–65). All patients except one were mobilized with chemotherapy plus granulocyte colony-stimulating factor (G-CSF). ELR was observed in 41% of the patients. Univariate analysis identified an association between the following factors and ELR: median pre-mobilization ALC (1920 vs 1060 lymphocytes/μL; p=0.003), pre-collection ALC (1637 vs 747 lymphocytes/μL; p<0.001), dose of leukocytes infused (1.21 x 109 vs 0.65 x 109 leukocytes/kg; p=0.002), dose of lymphocytes infused (0.26 x 109 vs 0.10 x 109 lymphocytes/kg; p<0.001), dose of CD4+ lymphocytes infused (0.075 x 109 vs 0.034 x 109 CD4+ lymphocytes/kg; p<0.001) and dose of CD8+ lymphocytes infused (0.11 x 109 vs 0.03 x 109 CD8+ lymphocytes/kg; p<0.001) were all higher in the ELR group. Patient diagnosis, number of previous cycles of chemotherapy and number of CD34+ cells collected were not correlated with ELR. Forward stepwise regression identified the pre-mobilization ALC and the number of lymphocytes in the autograft as factors related to ELR (p=0.013 and p<0.001; respectively). Multivariate analysis demonstrated that the lymphocyte dose in the graft can be predicted by the pre-collection ALC and the number of aphereses carried out (p<0.001 for both). Median pre-mobilization ALC was higher than pre-collection ALC (1335 vs 975 lymphocytes/μL respectively; p=0.013). This difference was most significant in the group of patients without ELR (1060 vs 747 lymphocytes/μL respectively; p=0.004). Among patients with ELR, the difference was not significant (1920 vs 1637 lymphocytes/μL respectively; p=0.53). Conclusions: These results indicate that ELR after ASCT depends on the pre-mobilization ALC and the lymphocyte dose in the autograft. The number of aphereses performed for stem cell collection and the pre-collection ALC predict the number of lymphocytes collected. Stem cell mobilization with chemotherapy and G-CSF significantly reduces the ALC at the time of collection, specially in patients with lower ALC at the time of the mobilization. Strategies to improve immunologic recovery may have an impact on the results of ASCT. Figure Figure


2009 ◽  
Vol 84 (1) ◽  
pp. 21-28 ◽  
Author(s):  
Elias Hallack Atta ◽  
Alexandre Mello de Azevedo ◽  
Angelo Maiolino ◽  
Cláudia Júlia Bruzzi Porto Coelho ◽  
Silvia Maria Patiño Sarcinelli ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1102-1102
Author(s):  
Gizelle Popradi ◽  
Dong Hwan (Dennis) Kim ◽  
John Kuruvilla ◽  
Vikas Gupta ◽  
Mark Minden ◽  
...  

Background: Early recovery of absolute lymphocyte count (ALC) is associated with improved outcomes following allogeneic and autologous stem cell transplantation for various hematological malignancies. The mechanism(s) underlying this observation is (are) unknown, but lymphocyte recovery may be a marker of immune reconstitution or graft-versus-leukemia activity. Objective: We assessed the incidence of early ALC recovery (defined as ALC ≥ 0.5 x 109/l by day+30) after peripheral blood stem cell transplantation (PBSCT) in recipients transplanted for AML or MDS and investigated its role as a potential prognostic marker for post PBSCT outcomes. Methods: We reviewed the cases of 110 consecutive patients who underwent first allogeneic PBSCT from related donors for a diagnosis of AML (n=92) or MDS (n=18) at the Princess Margaret Hospital (Toronto, Canada) between 2000 and 2007. All patients received related donor transplants (matched related, n=103; mismatched related, n=7) and were alive at day+30. The primary outcome measure was incidence of early ALC recovery at day +30 post PBSCT. Endpoints were overall survival (OS), non-relapse mortality (NRM) and relapse incidence (RI) after PBSCT according to day +30 ALC ≥ 0.5 x 109/l (high ALC group) or < 0.5 x 109/l (low ALC group). Results: The cohort included 51 women and 59 men. Median age at PBSCT was 51.7 years (range 18–71 years). Myeloablative conditioning (MAC) was employed in 65 (59%) patients (TBI based, n=62; Busulfan based, n=3), and 45 (41%) received reduced intensity conditioning (RIC). Median follow-up for survivors was 32 months. ALC ≥ 0.5 x 109/l by day+30 was reached by 72 patients (66%). There was no association between recipients’ gender, age at PBSCT or type of conditioning regimen and the probability of attaining ALC ≥ 0.5 x 109/l by day+30. Two-year OS in the entire cohort was 61%. Two-year OS of the high ALC group was superior to that of the low ALC group (72% vs. 40%, p=0.0003) (Figure 1A). The high ALC group also had significantly lower NRM (16% vs. 35%, p=0.005) (Figure 1B) and RI (21% vs. 42%, p=0.003) compared to the low ALC group (Figure 1C). No association between early ALC recovery and the incidences of acute or chronic graft-versus-host disease or incidence of CMV reactivation was observed. On multivariate analyses, low ALC at day +30 (ALC < 0.5 x 109/l) was an independent prognostic factor for inferior OS (p=0.02, HROS=2.27), higher RI (p= 0.01, HRRI=3.18), and higher NRM (p=0.03, HRNRM=2.1). Conclusion: In AML and MDS early lymphocyte recovery by day 30 is associated with improved OS. Failure to attain early ALC recovery may identify patients with higher risk of relapse and NRM after PBSCT. Figure 1. Comparison of transplant outcomes between groups with high and low ALC counts at day 30 in terms of survival (A), non-relapse (C). Figure 1. Comparison of transplant outcomes between groups with high and low ALC counts at day 30 in terms of survival (A), non-relapse (C).


Sign in / Sign up

Export Citation Format

Share Document